Dynamic Technology Lab Private Ltd Invests $502,000 in Revolution Medicines, Inc. $RVMD

Key Points

• Dynamic Technology Lab Private Ltd has invested approximately $502,000 in Revolution Medicines, acquiring 14,188 shares of stock.
• Institutional ownership of Revolution Medicines is significant, with over 94% of the stock held by institutional investors, including new stakes from several firms.
• Analysts have a consensus rating of "Buy" for Revolution Medicines, with an average target price of $72.00, and various institutions have set target prices ranging from $56.00 to $80.00.

Dynamic Technology Lab Private Ltd bought a new stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 14,188 shares of the company's stock, valued at approximately $502,000.

Other institutional investors also recently bought and sold shares of the company. Deutsche Bank AG boosted its position in Revolution Medicines by 57.8% during the 4th quarter. Deutsche Bank AG now owns 177,383 shares of the company's stock valued at $7,759,000 after acquiring an additional 64,997 shares in the last quarter. Jefferies Financial Group Inc. bought a new stake in shares of Revolution Medicines during the fourth quarter valued at approximately $994,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Revolution Medicines by 13.4% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 102,127 shares of the company's stock worth $4,463,000 after purchasing an additional 12,084 shares during the period. Nuveen Asset Management LLC grew its stake in Revolution Medicines by 3.1% in the fourth quarter. Nuveen Asset Management LLC now owns 473,728 shares of the company's stock worth $20,721,000 after purchasing an additional 14,391 shares during the period. Finally, Nicholas Investment Partners LP raised its holdings in Revolution Medicines by 36.0% in the fourth quarter. Nicholas Investment Partners LP now owns 84,729 shares of the company's stock worth $3,706,000 after purchasing an additional 22,429 shares in the last quarter. 94.34% of the stock is owned by institutional investors.

Insider Buying and Selling at Revolution Medicines

In other news, CFO Jack Anders sold 5,238 shares of the business's stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $40.17, for a total value of $210,410.46. Following the completion of the transaction, the chief financial officer owned 113,314 shares in the company, valued at $4,551,823.38. The trade was a 4.42% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 8.20% of the stock is owned by corporate insiders.

Analyst Ratings Changes

RVMD has been the topic of a number of research reports. Lifesci Capital assumed coverage on shares of Revolution Medicines in a report on Monday, August 18th. They set an "outperform" rating and a $80.00 target price on the stock. Wells Fargo & Company initiated coverage on shares of Revolution Medicines in a research note on Friday, August 15th. They set an "overweight" rating and a $67.00 price objective on the stock. Guggenheim reaffirmed a "buy" rating and set a $80.00 target price on shares of Revolution Medicines in a research note on Wednesday, June 25th. Needham & Company LLC lowered their target price on shares of Revolution Medicines from $57.00 to $56.00 and set a "buy" rating for the company in a report on Thursday, August 7th. Finally, The Goldman Sachs Group assumed coverage on Revolution Medicines in a research note on Tuesday, July 15th. They issued a "buy" rating and a $65.00 price target on the stock. Fourteen investment analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $72.00.

Revolution Medicines Trading Down 1.2%

Shares of NASDAQ RVMD opened at $40.45 on Thursday. The firm's 50 day moving average price is $37.56 and its 200-day moving average price is $38.12. Revolution Medicines, Inc. has a 52-week low of $29.17 and a 52-week high of $62.40. The company has a debt-to-equity ratio of 0.13, a quick ratio of 11.79 and a current ratio of 11.79. The company has a market cap of $7.56 billion, a PE ratio of -8.99 and a beta of 1.12.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($1.31) earnings per share for the quarter, missing analysts' consensus estimates of ($0.94) by ($0.37). Revolution Medicines's revenue was up .0% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.81) EPS. On average, equities research analysts expect that Revolution Medicines, Inc. will post -3.49 EPS for the current fiscal year.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.